首页> 外文期刊>Chinese journal of cancer >Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma
【24h】

Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma

机译:经导管动脉化疗栓塞联合CT引导下经皮热消融联合肝切除术治疗肝细胞癌

获取原文
       

摘要

IntroductionTranscatheter arterial chemoembolization (TACE) plus thermal ablation has been widely used recently in the treatment of hepatocellular carcinoma (HCC). In this study, we aimed to compare results of the combination of TACE and percutaneous thermal ablation with those of hepatectomy in patients with HCC. MethodsThe clinical data of 137 HCC patients who sequentially received TACE and computed tomography (CT)-guided percutaneous thermal ablation as an initial curative treatment (combination group) and 148 matched HCC patients who received hepatectomy (surgery group) between 2004 and 2011 were collected and analyzed. After TACE, multiphase contrast-enhanced CT was performed to identify the total number of tumors as well as lipiodol deposition in the liver. Survival was calculated by using the Kaplan-Meier method and compared by using the log-rank test. The prognostic factors were assessed with multivariate Cox proportional hazards regression analysis. ResultsOf all 285 patients, 225 (79.0?%) had cancerous lesions?≤?5?cm in diameter. In preoperative contrast-enhanced CT or magnetic resonance imaging, the number of tumors was 1–4 for each patient. The 1-, 3-, and 5-year overall survival rates were 95, 74?%, and 67?% in the combination group and 88, 66, and 47?% in the surgery group, respectively ( P =?0.004); the corresponding recurrence-free survival rates for the two groups were 92, 69, and 61?% and 75, 58, and 44?%, respectively ( P =?0.001). In the multivariate analysis, treatment allocation was an independent prognostic factor for survival. Only 60 patients in the combination group had sufficient imaging data, and 135 new lesions with lipiodol deposition were diagnosed as malignancies in 22 of 60 patients, whereas 20 new lesions were found in 11 of 148 patients in the surgery group. ConclusionThe combination of TACE and CT-guided percutaneous thermal ablation for HCC improves survival of HCC patients compared with hepatectomy.
机译:导言经导管动脉化疗栓塞(TACE)加上热消融术最近已广泛用于肝细胞癌(HCC)的治疗。在这项研究中,我们旨在比较肝癌患者TACE和经皮热消融联合肝切除术的结果。方法收集2004年至2011年间137例先后接受TACE和计算机断层扫描(CT)引导的经皮热消融作为初始治疗方法的HCC患者(联合治疗组)和148例相匹配的HCC肝切除患者(手术组)的临床资料,分析。 TACE后,进行多相造影剂增强CT检查,以鉴定肿瘤总数以及肝脏中的碘油沉积。使用Kaplan-Meier方法计算生存率,并使用对数秩检验进行比较。通过多因素Cox比例风险回归分析评估预后因素。结果在285例患者中,有225例(占79.0%)的癌灶直径≤5?cm。在术前对比增强CT或磁共振成像中,每例患者的肿瘤数量为1-4。联合组1、3年和5年总生存率分别为95%,74%和67%,而手术组分别为88%,66%和47%(P = 0.004)。 ;两组相应的无复发生存率分别为92%,69%和61%,75%,58%和44%(P = 0.001)。在多变量分析中,治疗分配是生存的独立预后因素。组合组中只有60例患者具有足够的影像学数据,在60例患者中有22例被诊断为含碘油沉积的135个新病灶为恶性肿瘤,而在手术组148例患者中有11例被诊断为新病灶。结论与肝切除术相比,TACE和CT引导的经皮热消融联合治疗HCC可以提高HCC患者的生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号